Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock
Close on Nov 13, 2026Market cap $4.54MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $4.54M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.24
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$10.26M
- EPS, diluted
- -$71.60
- Book value per share
- $18.90
- Diluted shares
- 1M
Trading
- Previous close
- $4.76
- Open
- $4.64
- Day's range
- $4.53 – $4.65
- Volume
- 10,278
- Average volume (20 days)
- 28,290
- Beta (5 years)
- 2.21
- 52-week range
- $2.58 – $44.40
- RSI (14 days)
- 43.4
- Volatility (1 year)
- 141.6%
- Relative volume
- 0.01×
- WACC
- 16.1%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SHPH | S&P 500 | Difference | SHPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.5% | -3.0% | −9.5 pts | ||
| 3 months | -1.1% | -2.8% | +1.7 pts | ||
| Year to date | -74.8% | +11.5% | −86.3 pts | ||
| 1 year | -80.4% | +13.5% | −93.9 pts | ||
| 3 years | -99.5% | +77.7% | −177.2 pts | -83.5% | +21.1% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Shuttle Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Shuttle Pharmaceuticals
Pharmaceutical Preparations
Shuttle Pharmaceuticals Holdings, Inc. operates as a pharmaceutical software and drug discovery enterprise centered around Molecule.ai, an artificial intelligence platform acquired in November 2025. The company previously developed clinical-stage therapeutic candidates, notably Ropidoxuridine, prior to initiating a wind-down of its clinical trials. Molecule.ai integrates a unified inference engine, an API-first framework, and modular predictive models to support molecular property prediction, multi-compound comparative analysis, and structured scientific reasoning. These software solutions serve researchers and pharmaceutical research and development teams navigating chemical exploration and early-stage drug design.
Company profile, executives and historyShuttle Pharmaceuticals stock: common questions
What is Shuttle Pharmaceuticals's stock price?
SHPH closed at $4.53 on Nov 13, 2026, down 4.83% on the day. Over the past 52 weeks it traded between $2.58 and $44.40.
What is Shuttle Pharmaceuticals's market cap?
Shuttle Pharmaceuticals was worth $4.54M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SHPH's P/E ratio?
Shuttle Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$71.60), so it has no meaningful P/E ratio.
Does Shuttle Pharmaceuticals pay a dividend?
No. Shuttle Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has SHPH stock performed over the past year?
Including dividends, SHPH returned -80.4% over the past year, against +13.5% for the S&P 500.
Who are Shuttle Pharmaceuticals's competitors?
Companies most similar to Shuttle Pharmaceuticals by business, industry and size include KALA, NBP, CDT, BFRG, COCP.
See a number that looks wrong?